SPRO
Spero Therapeutics, Inc.NASDAQHealthcare$2.43-0.82%ClosedMarket Cap: $140.7M
As of 2026-04-06
Valuation
P/E (TTM)
16.41
PEG
0.15
P/B
2.48
P/S
2.50
EV/EBITDA
20.80
DCF Value
$-31.36
FCF Yield
-8.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.5%
Operating Margin
-0.0%
Net Margin
14.2%
ROE
22.5%
ROA
12.4%
ROIC
-0.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $39.7M | 100.0% | $25.1M | $31.5M | $0.53 | — |
| FY 2025 | $59.6M | 100.0% | $-24.0K | $8.6M | $0.15 | — |
| Q3 2025 | $3.0M | 100.0% | $-7.9M | $-7.4M | $-0.13 | — |
| Q2 2025 | $11.8M | 100.0% | $-2.4M | $-1.7M | $-0.03 | — |
| Q1 2025 | $5.9M | -131.6% | $-14.7M | $-13.9M | $-0.25 | — |
| Q4 2024 | $15.0M | -529.0% | $-21.7M | $-20.9M | $-0.39 | — |
| FY 2024 | $48.0M | -101.7% | $-73.4M | $-68.6M | $-1.27 | — |
| Q3 2024 | $13.5M | 100.0% | $-18.6M | $-17.1M | $-0.32 | — |
| Q2 2024 | $10.2M | -132.7% | $-19.1M | $-17.9M | $-0.33 | — |
| Q1 2024 | $4.2M | 100.0% | $-14.0M | $-12.7M | $-0.24 | — |
| Q4 2023 | $73.5M | 32.8% | $50.5M | $51.2M | $0.96 | — |
| FY 2023 | $103.8M | 50.4% | $21.5M | $22.8M | $0.43 | — |